<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170571</url>
  </required_header>
  <id_info>
    <org_study_id>1160.51</org_study_id>
    <nct_id>NCT02170571</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function in a Monocentric, Open, Parallel-group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Assessment of the effect of moderate liver impairment (Child-Pugh classification B) on the&#xD;
      pharmacokinetics and pharmacodynamics of dabigatran after oral administration of dabigatran&#xD;
      etexilate. Determination of safety and tolerability of dabigatran upon administration to&#xD;
      hepatically impaired patients and healthy subjects (matched pairs)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-infinity (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration-response relationship of dabigatran assessed by analysis of activated partial thromboplastin time (aPTT), ecarin clotting time (ECT) , prothrombin time (PT) expressed as international normalised ratio (INR), and thrombin time (TT)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 (Area under the concentration time curve of the analyte in plasma over the time interval t1 to t2)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz ( terminal rate constant in plasma)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 ( terminal half-life of the analyte in plasma)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after oral administration)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-72 (amount of analyte that is eliminated in urine from the time interval 0 to 72 h)</measure>
    <time_frame>pre-dose over 12 h from day -1 till day 1 and post-dose from day 1 till day 4 in fractions of 0 - 12, 12 - 24, 24 - 48 and 48 - 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe0-72 (fraction of administered drug excreted unchanged in urine from time point 0 to 72 h)</measure>
    <time_frame>pre-dose over 12 h from day -1 till day 1 and post-dose from day 1 till day 4 in fractions of 0 - 12, 12 - 24, 24 - 48 and 48 - 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,0-72 (renal clearance of the analyte in plasma from the time point 0 h until the time point 72 h)</measure>
    <time_frame>pre-dose over 12 h from day -1 till day 1 and post-dose from day 1 till day 4 in fractions of 0 - 12, 12 - 24, 24 - 48 and 48 - 72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein binding of dabigatran</measure>
    <time_frame>before drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse rate</measure>
    <time_frame>up to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>up to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG</measure>
    <time_frame>up to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a four-point scale</measure>
    <time_frame>up to day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy age-, weight-, and sex-matched subjects determined by results of screening&#xD;
             with normal hepatic function (group 1)&#xD;
&#xD;
          -  Hepatically impaired subjects determined by results of screening classified as&#xD;
             Child-Pugh B (group 2)&#xD;
&#xD;
          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and&#xD;
             local legislation&#xD;
&#xD;
          -  Age &gt;=18 and &lt;=75 years&#xD;
&#xD;
          -  BMI &gt;=18.0 and &lt;=32 kg/m2, at least 45 kg for females&#xD;
&#xD;
          -  Creatinine clearance &gt;80 mL/min according to Cockcroft &amp; Gault&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects (Group 1) who met any of the following criteria should not be entered&#xD;
             into this trial:&#xD;
&#xD;
               -  Any finding of the medical examination (including blood pressure, pulse rate, and&#xD;
                  electrocardiogram) deviating from normal and of clinical relevance&#xD;
&#xD;
               -  Clinically relevant gastrointestinal, hepatic, renal, respiratory,&#xD;
                  cardiovascular, metabolic, immunologic or hormonal disorders&#xD;
&#xD;
               -  Surgery of gastrointestinal tract (except appendectomy, cholecystectomy,&#xD;
                  herniotomy)&#xD;
&#xD;
               -  Clinically relevant diseases of the central nervous system&#xD;
&#xD;
               -  Relevant history of orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
               -  Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia,&#xD;
                  cerebrovascular haemorrhage, bleeding tendencies associated with active&#xD;
                  ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary&#xD;
                  tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral&#xD;
                  aneurysm, dissecting aorta, central nervous system (CNS) trauma, retinopathy,&#xD;
                  nephrolithiasis)&#xD;
&#xD;
               -  Recent or contemplated diagnostic or therapeutic procedures with potential for&#xD;
                  uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery&#xD;
                  of CNS or eye or surgery resulting in large open surfaces) within 14 days before&#xD;
                  or after drug administration of this clinical trial&#xD;
&#xD;
               -  Chronic or relevant acute infections&#xD;
&#xD;
               -  History of allergy/hypersensitivity (including drug allergy), which is deemed&#xD;
                  relevant to the trial as judged by the investigator&#xD;
&#xD;
               -  For women with childbearing potential: no reliable contraception (accepted&#xD;
                  methods are intra-uterine device, hormonal contraceptives, bilateral tubal&#xD;
                  ligation, hysterectomy, condoms) or pregnancy (known or detected by a positive&#xD;
                  pregnancy test) or breast feeding period&#xD;
&#xD;
               -  Intake of drugs with a long half-life (&gt; 24 hours) (&lt; 1 month prior to&#xD;
                  administration or during the trial)&#xD;
&#xD;
               -  Use of any drugs, within 14 days prior to administration or during the trial&#xD;
&#xD;
               -  Participation in another trial with an investigational drug (&lt; 2 months prior to&#xD;
                  administration or during trial)&#xD;
&#xD;
               -  Drug abuse&#xD;
&#xD;
               -  Blood donation or loss &gt; 400 ml, &lt; 1 month prior to administration or during the&#xD;
                  trial&#xD;
&#xD;
               -  Excessive physical activities &lt; 5 days prior to administration of study drug or&#xD;
                  during the trial&#xD;
&#xD;
               -  Clinically relevant laboratory abnormalities&#xD;
&#xD;
               -  Veins unsuited for i.v. puncture and administration of prolonged infusions on&#xD;
                  either arm (e.g. veins which are difficult to locate, access or puncture, veins&#xD;
                  with a tendency to rupture during or after puncture, etc.)&#xD;
&#xD;
          -  Hepatically impaired subjects (Group 2) who met any of the following criteria should&#xD;
             not be entered into this trial:&#xD;
&#xD;
               -  Moderate and severe concurrent renal function impairment (e.g., due to&#xD;
                  hepato-renal syndrome)&#xD;
&#xD;
               -  Clinically relevant gastrointestinal, respiratory, cardiovascular, metabolic,&#xD;
                  immunologic or hormonal disorders&#xD;
&#xD;
               -  Surgery of gastrointestinal tract (except appendectomy, cholecystectomy,&#xD;
                  herniotomy)&#xD;
&#xD;
               -  Clinically relevant diseases of the central nervous system&#xD;
&#xD;
               -  Relevant history of orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
               -  Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia,&#xD;
                  cerebrovascular haemorrhage, bleeding tendencies associated with active&#xD;
                  ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary&#xD;
                  tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral&#xD;
                  aneurysm, dissecting aorta, CNS trauma, retinopathy, nephrolithiasis) considered&#xD;
                  by the investigator or one of the coinvestigators to be clinically relevant&#xD;
&#xD;
               -  Recent or contemplated diagnostic or therapeutic procedures with potential for&#xD;
                  uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery&#xD;
                  of CNS or eye or surgery resulting in large open surfaces) within 14 days before&#xD;
                  or after drug administration of this clinical trial&#xD;
&#xD;
               -  History of allergy/hypersensitivity (including drug allergy) which is deemed&#xD;
                  relevant to the trial as judged by the investigator&#xD;
&#xD;
               -  For women with childbearing potential: no reliable contraception (accepted&#xD;
                  methods are intra-uterine device, hormonal contraceptives, bilateral tubal&#xD;
                  ligation, hysterectomy, condoms) or pregnancy (known or detected by a positive&#xD;
                  pregnancy test) or breast feeding period&#xD;
&#xD;
               -  Use of any drugs which have an influence on the blood clotting within 14 days&#xD;
                  prior to administration or during the trial&#xD;
&#xD;
               -  Participation in another trial with an investigational drug (&lt; 2 months prior to&#xD;
                  administration or during trial)&#xD;
&#xD;
               -  Blood donation or loss &gt; 400 ml, &lt; 1 month prior to administration or during the&#xD;
                  trial&#xD;
&#xD;
               -  Excessive physical activities &lt; 5 days prior to administration of study drug or&#xD;
                  during the trial&#xD;
&#xD;
               -  Clinically relevant laboratory abnormalities (except for liver function tests&#xD;
                  according to Child-Pugh classification), constellation of blood clotting&#xD;
                  parameters according to the judgment of the investigator&#xD;
&#xD;
               -  Veins unsuited for i.v. puncture and administration of prolonged infusions on&#xD;
                  either arm (e.g. veins which are difficult to locate, access or puncture, veins&#xD;
                  with a tendency to rupture during or after puncture, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.51_U06-1705-01.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

